- Home
- SLNO
as 06-20-2025 4:00pm EST
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.8B | IPO Year: | 2014 |
| Target Price: | $103.33 | AVG Volume (30 days): | 763.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.93 - $81.54 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SLNO | SEE REMARKS | Apr 1 '25 | Sell | $70.11 | 3,782 | $265,156.02 | 27,036 | |
| Pauls Matthew | SLNO | Director | Mar 28 '25 | Sell | $71.55 | 5,937 | $424,797.10 | 6,500 | |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Mar 27 '25 | Sell | $69.46 | 90,622 | $6,293,177.03 | 113,220 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Mar 27 '25 | Sell | $68.58 | 699,095 | $47,271,960.10 | 715,084 | |
| Yen Kristen | SLNO | SEE REMARKS | Mar 27 '25 | Sell | $68.72 | 95,500 | $6,376,788.66 | 61,227 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Mar 27 '25 | Sell | $69.39 | 156,315 | $10,709,353.03 | 27,036 | |
| Manning Meredith | SLNO | Chief Commercial Officer | Mar 27 '25 | Sell | $69.03 | 45,249 | $3,044,342.88 | 52,932 | |
| Huang Michael F. | SLNO | Sr. VP of Clinical Development | Mar 27 '25 | Sell | $69.36 | 14,583 | $1,013,627.05 | 39,327 | |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Mar 26 '25 | Sell | $68.07 | 1,833,557 | $124,449,124.20 | 4,791,851 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
GlobeNewswire
a day ago
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Simply Wall St.
8 days ago
High Growth Tech Stocks in US for June 2025
Pharmaceutical Technology
a month ago
EMA validates Soleno’s application for Prader-Willi syndrome treatment
TipRanks
a month ago
Soleno Therapeutics seeking regulatory approval in treatment of PWS
MT Newswires
a month ago
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday
MT Newswires
a month ago
Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation
Insider Monkey
a month ago
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.